{"transactions":[{"id":698632,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Non Qualified Stock Option (Right to Buy)","published_at":"2026-08-03T23:16:59.000Z","date":"2026-08-03","kind":"exercise","planned":false,"acquired":false,"shares":16524,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are fully vested in accordance with their terms."}],"balance_after":0,"derivative":{"exercise_price":46.72,"expiration_date":"2026-09-14","underlying":"Ordinary Shares","underlying_shares":16524},"source":{"system":"sec-edgar","filing":"0001520262-26-000111","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000152026226000111/form4.xml","form_type":"4"}},{"id":698631,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Non Qualified Stock Option (Right to Buy)","published_at":"2026-08-03T23:16:59.000Z","date":"2026-08-03","kind":"exercise","planned":false,"acquired":false,"shares":27948,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are fully vested in accordance with their terms."}],"balance_after":0,"derivative":{"exercise_price":46.72,"expiration_date":"2026-09-14","underlying":"Ordinary Shares","underlying_shares":27948},"source":{"system":"sec-edgar","filing":"0001520262-26-000111","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000152026226000111/form4.xml","form_type":"4"}},{"id":698630,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2026-08-03T23:16:59.000Z","date":"2026-08-03","kind":"sale","planned":false,"acquired":false,"shares":44472,"price":50.348,"value":2239076.256,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.07 to $50.70. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request."}],"balance_after":15395,"source":{"system":"sec-edgar","filing":"0001520262-26-000111","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000152026226000111/form4.xml","form_type":"4"}},{"id":698629,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2026-08-03T23:16:59.000Z","date":"2026-08-03","kind":"exercise","planned":false,"acquired":true,"shares":16524,"price":46.72,"value":772001.28,"ownership":{"direct":true},"balance_after":59867,"source":{"system":"sec-edgar","filing":"0001520262-26-000111","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000152026226000111/form4.xml","form_type":"4"}},{"id":698628,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2026-08-03T23:16:59.000Z","date":"2026-08-03","kind":"exercise","planned":false,"acquired":true,"shares":27948,"price":46.72,"value":1305730.56,"ownership":{"direct":true},"balance_after":43343,"source":{"system":"sec-edgar","filing":"0001520262-26-000111","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000152026226000111/form4.xml","form_type":"4"}},{"id":765462,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Restricted Stock Unit Award","published_at":"2026-05-23T00:04:37.000Z","date":"2026-05-21","kind":"exercise","planned":false,"acquired":false,"shares":6142,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This award is fully vested in accordance with its terms."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This award is fully vested in accordance with its terms."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":6142},"source":{"system":"sec-edgar","filing":"0001520262-26-000091","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000152026226000091/form4.xml","form_type":"4"}},{"id":765461,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Restricted Stock Unit Award","published_at":"2026-05-23T00:04:37.000Z","date":"2026-05-20","kind":"grant","planned":false,"acquired":true,"shares":5409,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant."}],"balance_after":5409,"derivative":{"underlying":"Ordinary Shares","underlying_shares":5409},"source":{"system":"sec-edgar","filing":"0001520262-26-000091","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000152026226000091/form4.xml","form_type":"4"}},{"id":765460,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Non Qualified Stock Option (Right to Buy)","published_at":"2026-05-23T00:04:37.000Z","date":"2026-05-20","kind":"grant","planned":false,"acquired":true,"shares":11538,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant."}],"balance_after":11538,"derivative":{"exercise_price":36.98,"expiration_date":"2036-05-20","underlying":"Ordinary Shares","underlying_shares":11538},"source":{"system":"sec-edgar","filing":"0001520262-26-000091","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000152026226000091/form4.xml","form_type":"4"}},{"id":765459,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2026-05-23T00:04:37.000Z","date":"2026-05-21","kind":"tax_withholding","planned":false,"acquired":false,"shares":1475,"price":36.95,"value":54501.25,"ownership":{"direct":true},"balance_after":15395,"source":{"system":"sec-edgar","filing":"0001520262-26-000091","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000152026226000091/form4.xml","form_type":"4"}},{"id":765458,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2026-05-23T00:04:37.000Z","date":"2026-05-21","kind":"exercise","planned":false,"acquired":true,"shares":6142,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share."}],"balance_after":16870,"source":{"system":"sec-edgar","filing":"0001520262-26-000091","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000152026226000091/form4.xml","form_type":"4"}},{"id":1127263,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Restricted Stock Unit Award","published_at":"2025-06-02T20:32:50.000Z","date":"2025-05-31","kind":"exercise","planned":false,"acquired":false,"shares":8013,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This award is fully vested in accordance with its terms."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This award is fully vested in accordance with its terms."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":8013},"source":{"system":"sec-edgar","filing":"0001127602-25-016204","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760225016204/form4.xml","form_type":"4"}},{"id":1127262,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2025-06-02T20:32:50.000Z","date":"2025-05-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":1924,"price":30.61,"value":58893.64,"ownership":{"direct":true},"balance_after":10728,"source":{"system":"sec-edgar","filing":"0001127602-25-016204","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760225016204/form4.xml","form_type":"4"}},{"id":1127261,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2025-06-02T20:32:50.000Z","date":"2025-05-31","kind":"exercise","planned":false,"acquired":true,"shares":8013,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share."}],"balance_after":12652,"source":{"system":"sec-edgar","filing":"0001127602-25-016204","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760225016204/form4.xml","form_type":"4"}},{"id":1134839,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Restricted Stock Unit Award","published_at":"2025-05-23T21:59:58.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":6142,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares subject to the restricted stock unit award vest in full on 5/21/2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares subject to the restricted stock unit award vest in full on 5/21/2026."}],"balance_after":6142,"derivative":{"exercise_date":"2026-05-21","underlying":"Ordinary Shares","underlying_shares":6142},"source":{"system":"sec-edgar","filing":"0001127602-25-015543","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760225015543/form4.xml","form_type":"4"}},{"id":1134838,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Non Qualified Stock Option (Right to Buy)","published_at":"2025-05-23T21:59:58.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":13474,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the stock option award vest and become exercisable in full on 5/21/2026."}],"balance_after":13474,"derivative":{"exercise_price":30.53,"exercise_date":"2026-05-21","expiration_date":"2035-05-21","underlying":"Ordinary Shares","underlying_shares":13474},"source":{"system":"sec-edgar","filing":"0001127602-25-015543","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760225015543/form4.xml","form_type":"4"}},{"id":1144994,"issuer":{"id":46837,"kind":"organization","name":"Lyra Therapeutics, Inc.","symbol":"LYRA"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-05-16T20:30:31.000Z","date":"2025-05-14","kind":"grant","planned":false,"acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 100% on the earlier of (i) the day before the Issuer's next annual meeting, (ii) May 14, 2026 and (iii) upon a Change in Control as defined in the 2020 Incentive Award Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 100% on the earlier of (i) the day before the Issuer's next annual meeting, (ii) May 14, 2026 and (iii) upon a Change in Control as defined in the 2020 Incentive Award Plan."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 100% on the earlier of (i) the day before the Issuer's next annual meeting, (ii) May 14, 2026 and (iii) upon a Change in Control as defined in the 2020 Incentive Award Plan."}],"balance_after":32000,"derivative":{"underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0000950170-25-073608","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1327273/000095017025073608/ownership.xml","form_type":"4"}},{"id":1363218,"issuer":{"id":86004,"kind":"organization","name":"Axonics, Inc.","symbol":"AXNX"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-15T09:00:06.000Z","date":"2024-11-15","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"price":49.96,"value":499600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a \"Company Option\"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a \"Company Option\"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a \"Company Option\"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions."}],"balance_after":0,"derivative":{"exercise_price":21.04,"expiration_date":"2029-04-08","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-24-007710","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1603756/000156218024007710/primarydocument.xml","form_type":"4"}},{"id":1363217,"issuer":{"id":86004,"kind":"organization","name":"Axonics, Inc.","symbol":"AXNX"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-15T09:00:06.000Z","date":"2024-11-15","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4167,"price":36.9,"value":153762.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a \"Company Option\"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a \"Company Option\"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a \"Company Option\"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions."}],"balance_after":0,"derivative":{"exercise_price":34.1,"expiration_date":"2029-08-22","underlying":"Common Stock","underlying_shares":4167},"source":{"system":"sec-edgar","filing":"0001562180-24-007710","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1603756/000156218024007710/primarydocument.xml","form_type":"4"}},{"id":1363216,"issuer":{"id":86004,"kind":"organization","name":"Axonics, Inc.","symbol":"AXNX"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-15T09:00:06.000Z","date":"2024-11-15","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14944,"price":71,"value":1061024.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of the reporting person's shares of the Issuer's common stock, upon the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 8, 2024 (the \"Merger Agreement\"), among the Issuer, Boston Scientific Corporation (\"Parent\") and Sadie Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), including the consummation of the merger of Merger Sub with and into the Issuer with the Issuer as the surviving corporation (the \"Merger\").  Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective time\"), each outstanding share of the Issuer's common stock was canceled and converted automatically into the right to receive $71.00 in cash, without interest (The \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the disposition of the reporting person's shares of the Issuer's common stock, upon the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 8, 2024 (the \"Merger Agreement\"), among the Issuer, Boston Scientific Corporation (\"Parent\") and Sadie Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), including the consummation of the merger of Merger Sub with and into the Issuer with the Issuer as the surviving corporation (the \"Merger\").  Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective time\"), each outstanding share of the Issuer's common stock was canceled and converted automatically into the right to receive $71.00 in cash, without interest (The \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-24-007710","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1603756/000156218024007710/primarydocument.xml","form_type":"4"}},{"id":1368193,"issuer":{"id":86004,"kind":"organization","name":"Axonics, Inc.","symbol":"AXNX"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-12T19:01:22.000Z","date":"2024-11-07","kind":"gift","planned":false,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":14944,"source":{"system":"sec-edgar","filing":"0001562180-24-007659","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1603756/000156218024007659/primarydocument.xml","form_type":"4"}},{"id":1465523,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Restricted Stock Unit Award","published_at":"2024-07-01T21:01:17.000Z","date":"2024-06-29","kind":"exercise","planned":false,"acquired":false,"shares":6104,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one ordinary share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This award is fully vested in accordance with its terms."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This award is fully vested in accordance with its terms."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":6104},"source":{"system":"sec-edgar","filing":"0001127602-24-019603","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760224019603/form4.xml","form_type":"4"}},{"id":1465522,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2024-07-01T21:01:17.000Z","date":"2024-06-29","kind":"tax_withholding","planned":false,"acquired":false,"shares":1465,"price":24.1,"value":35306.5,"ownership":{"direct":true},"balance_after":4639,"source":{"system":"sec-edgar","filing":"0001127602-24-019603","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760224019603/form4.xml","form_type":"4"}},{"id":1465521,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2024-07-01T21:01:17.000Z","date":"2024-06-29","kind":"exercise","planned":false,"acquired":true,"shares":6104,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one ordinary share."}],"balance_after":6104,"source":{"system":"sec-edgar","filing":"0001127602-24-019603","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760224019603/form4.xml","form_type":"4"}},{"id":1478685,"issuer":{"id":46837,"kind":"organization","name":"Lyra Therapeutics, Inc.","symbol":"LYRA"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2024-06-14T20:10:06.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable on the earlier of (i) June 13, 2025 (the one-year anniversary of the date of grant) and (ii) the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case, subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":0.31,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-24-073648","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1327273/000095017024073648/ownership.xml","form_type":"4"}},{"id":1491565,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Non Qualified Stock Option (Right to Buy)","published_at":"2024-06-04T21:01:28.000Z","date":"2024-05-31","kind":"grant","planned":false,"acquired":true,"shares":17492,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Shares subject to the stock option award vest and become exercisable in full on 5/31/2025."}],"balance_after":17492,"derivative":{"exercise_price":23.4,"exercise_date":"2025-05-31","expiration_date":"2034-05-31","underlying":"Ordinary Shares","underlying_shares":17492},"source":{"system":"sec-edgar","filing":"0001127602-24-017730","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760224017730/form4.xml","form_type":"4"}},{"id":1491564,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Restricted Stock Unit Award","published_at":"2024-06-04T21:01:28.000Z","date":"2024-05-31","kind":"grant","planned":false,"acquired":true,"shares":8013,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Shares subject to the restricted stock unit award vest in full on 5/31/2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Shares subject to the restricted stock unit award vest in full on 5/31/2025."}],"balance_after":8013,"derivative":{"exercise_date":"2025-05-31","underlying":"Ordinary Shares","underlying_shares":8013},"source":{"system":"sec-edgar","filing":"0001127602-24-017730","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760224017730/form4.xml","form_type":"4"}},{"id":1491563,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Restricted Stock Unit Award","published_at":"2024-06-04T21:01:28.000Z","date":"2023-11-17","kind":"other","planned":false,"acquired":true,"shares":119,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the \"Separation\"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one ordinary share."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Shares subject to the restricted stock unit award vest in full on 6/29/2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Shares subject to the restricted stock unit award vest in full on 6/29/2024."}],"balance_after":6104,"derivative":{"exercise_date":"2024-06-29","underlying":"Ordinary Shares","underlying_shares":119},"source":{"system":"sec-edgar","filing":"0001127602-24-017730","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760224017730/form4.xml","form_type":"4"}},{"id":1491562,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Non Qualified Stock Option (Right to Buy)","published_at":"2024-06-04T21:01:28.000Z","date":"2023-11-17","kind":"other","planned":false,"acquired":true,"shares":254,"price":30.72,"value":7802.88,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the \"Separation\"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares subject to the stock option award vest and become exercisable in full on 6/29/2024."}],"balance_after":12986,"derivative":{"exercise_price":30.72,"exercise_date":"2024-06-29","expiration_date":"2033-06-29","underlying":"Ordinary Shares","underlying_shares":254},"source":{"system":"sec-edgar","filing":"0001127602-24-017730","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760224017730/form4.xml","form_type":"4"}},{"id":1491561,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Non Qualified Stock Option (Right to Buy)","published_at":"2024-06-04T21:01:28.000Z","date":"2023-11-17","kind":"other","planned":false,"acquired":true,"shares":231,"price":30.86,"value":7128.66,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the \"Separation\"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options are fully vested in accordance with their terms."}],"balance_after":11785,"derivative":{"exercise_price":30.86,"expiration_date":"2032-07-07","underlying":"Ordinary Shares","underlying_shares":231},"source":{"system":"sec-edgar","filing":"0001127602-24-017730","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760224017730/form4.xml","form_type":"4"}},{"id":1491560,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Non Qualified Stock Option (Right to Buy)","published_at":"2024-06-04T21:01:28.000Z","date":"2023-11-17","kind":"other","planned":false,"acquired":true,"shares":313,"price":24.24,"value":7587.12,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the \"Separation\"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options are fully vested in accordance with their terms."}],"balance_after":15990,"derivative":{"exercise_price":24.24,"expiration_date":"2031-06-14","underlying":"Ordinary Shares","underlying_shares":313},"source":{"system":"sec-edgar","filing":"0001127602-24-017730","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760224017730/form4.xml","form_type":"4"}},{"id":1491559,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Non Qualified Stock Option (Right to Buy)","published_at":"2024-06-04T21:01:28.000Z","date":"2023-11-17","kind":"other","planned":false,"acquired":true,"shares":230,"price":18.45,"value":4243.5,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the \"Separation\"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options are fully vested in accordance with their terms."}],"balance_after":11739,"derivative":{"exercise_price":18.45,"expiration_date":"2030-12-02","underlying":"Ordinary Shares","underlying_shares":230},"source":{"system":"sec-edgar","filing":"0001127602-24-017730","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760224017730/form4.xml","form_type":"4"}},{"id":1491558,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Non Qualified Stock Option (Right to Buy)","published_at":"2024-06-04T21:01:28.000Z","date":"2023-11-17","kind":"other","planned":false,"acquired":true,"shares":256,"price":16.52,"value":4229.12,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the \"Separation\"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options are fully vested in accordance with their terms."}],"balance_after":13079,"derivative":{"exercise_price":16.52,"expiration_date":"2030-05-20","underlying":"Ordinary Shares","underlying_shares":256},"source":{"system":"sec-edgar","filing":"0001127602-24-017730","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760224017730/form4.xml","form_type":"4"}},{"id":1491557,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Non Qualified Stock Option (Right to Buy)","published_at":"2024-06-04T21:01:28.000Z","date":"2023-11-17","kind":"other","planned":false,"acquired":true,"shares":448,"price":24.55,"value":10998.4,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the \"Separation\"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options are fully vested in accordance with their terms."}],"balance_after":22848,"derivative":{"exercise_price":24.55,"expiration_date":"2029-05-22","underlying":"Ordinary Shares","underlying_shares":448},"source":{"system":"sec-edgar","filing":"0001127602-24-017730","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760224017730/form4.xml","form_type":"4"}},{"id":1491556,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Non Qualified Stock Option (Right to Buy)","published_at":"2024-06-04T21:01:28.000Z","date":"2023-11-17","kind":"other","planned":false,"acquired":true,"shares":350,"price":44.75,"value":15662.5,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the \"Separation\"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options are fully vested in accordance with their terms."}],"balance_after":17850,"derivative":{"exercise_price":44.75,"expiration_date":"2028-05-23","underlying":"Ordinary Shares","underlying_shares":350},"source":{"system":"sec-edgar","filing":"0001127602-24-017730","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760224017730/form4.xml","form_type":"4"}},{"id":1491555,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Non Qualified Stock Option (Right to Buy)","published_at":"2024-06-04T21:01:28.000Z","date":"2023-11-17","kind":"other","planned":false,"acquired":true,"shares":284,"price":57.11,"value":16219.24,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the \"Separation\"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options are fully vested in accordance with their terms."}],"balance_after":14484,"derivative":{"exercise_price":57.11,"expiration_date":"2027-05-24","underlying":"Ordinary Shares","underlying_shares":284},"source":{"system":"sec-edgar","filing":"0001127602-24-017730","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760224017730/form4.xml","form_type":"4"}},{"id":1491554,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Non Qualified Stock Option (Right to Buy)","published_at":"2024-06-04T21:01:28.000Z","date":"2023-11-17","kind":"other","planned":false,"acquired":true,"shares":324,"price":46.72,"value":15137.28,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the \"Separation\"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options are fully vested in accordance with their terms."}],"balance_after":16524,"derivative":{"exercise_price":46.72,"expiration_date":"2026-09-14","underlying":"Ordinary Shares","underlying_shares":324},"source":{"system":"sec-edgar","filing":"0001127602-24-017730","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760224017730/form4.xml","form_type":"4"}},{"id":1491553,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Non Qualified Stock Option (Right to Buy)","published_at":"2024-06-04T21:01:28.000Z","date":"2023-11-17","kind":"other","planned":false,"acquired":true,"shares":548,"price":46.72,"value":25602.56,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the \"Separation\"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options are fully vested in accordance with their terms."}],"balance_after":27948,"derivative":{"exercise_price":46.72,"expiration_date":"2026-09-14","underlying":"Ordinary Shares","underlying_shares":548},"source":{"system":"sec-edgar","filing":"0001127602-24-017730","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760224017730/form4.xml","form_type":"4"}},{"id":1832104,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Restricted Stock Unit Award","published_at":"2023-07-11T00:35:18.000Z","date":"2023-07-07","kind":"exercise","planned":false,"acquired":false,"shares":5957,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This award is fully vested in accordance with its terms."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This award is fully vested in accordance with its terms."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":5957},"source":{"system":"sec-edgar","filing":"0001127602-23-020550","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760223020550/form4.xml","form_type":"4"}},{"id":1832103,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2023-07-11T00:35:18.000Z","date":"2023-07-07","kind":"tax_withholding","planned":false,"acquired":false,"shares":1430,"price":29.88,"value":42728.4,"ownership":{"direct":true},"balance_after":20783,"source":{"system":"sec-edgar","filing":"0001127602-23-020550","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760223020550/form4.xml","form_type":"4"}},{"id":1832102,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2023-07-11T00:35:18.000Z","date":"2023-07-07","kind":"exercise","planned":false,"acquired":true,"shares":5957,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share."}],"balance_after":22213,"source":{"system":"sec-edgar","filing":"0001127602-23-020550","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760223020550/form4.xml","form_type":"4"}},{"id":1835441,"issuer":{"id":46837,"kind":"organization","name":"Lyra Therapeutics, Inc.","symbol":"LYRA"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2023-07-06T01:46:46.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable on June 30, 2024, subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date."}],"balance_after":20000,"derivative":{"exercise_price":4.11,"expiration_date":"2033-06-29","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-23-031862","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1327273/000095017023031862/ownership.xml","form_type":"4"}},{"id":1840858,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Restricted Stock Unit Award","published_at":"2023-06-30T20:36:05.000Z","date":"2023-06-29","kind":"grant","planned":false,"acquired":true,"shares":5985,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares subject to the restricted stock unit award vest in full on 6/29/2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares subject to the restricted stock unit award vest in full on 6/29/2024."}],"balance_after":5985,"derivative":{"exercise_date":"2024-06-29","underlying":"Ordinary Shares","underlying_shares":5985},"source":{"system":"sec-edgar","filing":"0001127602-23-019633","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760223019633/form4.xml","form_type":"4"}},{"id":1840857,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Non Qualified Stock Option (Right to Buy)","published_at":"2023-06-30T20:36:05.000Z","date":"2023-06-29","kind":"grant","planned":false,"acquired":true,"shares":12732,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the stock option award vest and become exercisable in full on 6/29/2024."}],"balance_after":12732,"derivative":{"exercise_price":31.33,"exercise_date":"2024-06-29","expiration_date":"2033-06-29","underlying":"Ordinary Shares","underlying_shares":12732},"source":{"system":"sec-edgar","filing":"0001127602-23-019633","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760223019633/form4.xml","form_type":"4"}},{"id":1842489,"issuer":{"id":86004,"kind":"organization","name":"Axonics, Inc.","symbol":"AXNX"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-28T20:21:41.000Z","date":"2023-06-26","kind":"grant","planned":false,"acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":19944,"source":{"system":"sec-edgar","filing":"0001562180-23-005532","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1603756/000156218023005532/primarydocument.xml","form_type":"4"}},{"id":2176708,"issuer":{"id":86004,"kind":"organization","name":"Axonics, Inc.","symbol":"AXNX"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-22T20:13:50.000Z","date":"2022-08-18","kind":"grant","acquired":true,"shares":2100,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16944,"source":{"system":"sec-edgar","filing":"0001562180-22-006264","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1603756/000156218022006264/primarydocument.xml","form_type":"4"}},{"id":2209685,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Non Qualified Stock Option (Right to Buy)","published_at":"2022-07-08T20:23:27.000Z","date":"2022-07-07","kind":"grant","acquired":true,"shares":11554,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares subject to the stock option award vest and become exercisable in full on 7/7/2023."}],"balance_after":11554,"derivative":{"exercise_price":31.48,"exercise_date":"2023-07-07","expiration_date":"2032-07-07","underlying":"Ordinary Shares","underlying_shares":11554},"source":{"system":"sec-edgar","filing":"0001127602-22-019131","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760222019131/form4.xml","form_type":"4"}},{"id":2209684,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Restricted Stock Unit Award","published_at":"2022-07-08T20:23:27.000Z","date":"2022-07-07","kind":"grant","acquired":true,"shares":5957,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares subject to the restricted stock unit award vest in full on 7/7/2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares subject to the restricted stock unit award vest in full on 7/7/2023."}],"balance_after":5957,"derivative":{"exercise_date":"2023-07-07","underlying":"Ordinary Shares","underlying_shares":5957},"source":{"system":"sec-edgar","filing":"0001127602-22-019131","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760222019131/form4.xml","form_type":"4"}},{"id":2225096,"issuer":{"id":46837,"kind":"organization","name":"Lyra Therapeutics, Inc.","symbol":"LYRA"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2022-06-21T20:05:41.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":7250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable on the earlier of (i) June 16, 2023 (the one-year anniversary of the date of grant) and (ii) the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date."}],"balance_after":7250,"derivative":{"exercise_price":5.09,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":7250},"source":{"system":"sec-edgar","filing":"0000899243-22-023331","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1327273/000089924322023331/doc4.xml","form_type":"4"}},{"id":2229587,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Restricted Stock Unit Award","published_at":"2022-06-16T20:58:51.000Z","date":"2022-06-14","kind":"exercise","acquired":false,"shares":7585,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This award is fully vested in accordance with its terms."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This award is fully vested in accordance with its terms."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":7585},"source":{"system":"sec-edgar","filing":"0001127602-22-017639","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760222017639/form4.xml","form_type":"4"}},{"id":2229586,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2022-06-16T20:58:51.000Z","date":"2022-06-14","kind":"tax_withholding","acquired":false,"shares":695,"price":27.19,"value":18897.05,"ownership":{"direct":true},"balance_after":16256,"source":{"system":"sec-edgar","filing":"0001127602-22-017639","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760222017639/form4.xml","form_type":"4"}},{"id":2229585,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2022-06-16T20:58:51.000Z","date":"2022-06-14","kind":"exercise","acquired":true,"shares":7585,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share."}],"balance_after":16951,"source":{"system":"sec-edgar","filing":"0001127602-22-017639","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760222017639/form4.xml","form_type":"4"}},{"id":2343816,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2022-03-08T21:13:50.000Z","date":"2022-03-04","kind":"purchase","acquired":true,"shares":427,"price":23.43,"value":10004.61,"ownership":{"direct":true},"balance_after":9366,"source":{"system":"sec-edgar","filing":"0001127602-22-008576","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760222008576/form4.xml","form_type":"4"}},{"id":2485101,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Restricted Stock Unit Award","published_at":"2021-12-04T02:26:13.000Z","date":"2021-12-02","kind":"exercise","acquired":false,"shares":5578,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This award is fully vested in accordance with its terms."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This award is fully vested in accordance with its terms."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":5578},"source":{"system":"sec-edgar","filing":"0001127602-21-030303","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760221030303/form4.xml","form_type":"4"}},{"id":2485100,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2021-12-04T02:26:13.000Z","date":"2021-12-02","kind":"tax_withholding","acquired":false,"shares":1339,"price":22.11,"value":29605.29,"ownership":{"direct":true},"balance_after":8939,"source":{"system":"sec-edgar","filing":"0001127602-21-030303","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760221030303/form4.xml","form_type":"4"}},{"id":2485099,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2021-12-04T02:26:13.000Z","date":"2021-12-02","kind":"exercise","acquired":true,"shares":5578,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share."}],"balance_after":10278,"source":{"system":"sec-edgar","filing":"0001127602-21-030303","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760221030303/form4.xml","form_type":"4"}},{"id":2528185,"issuer":{"id":86004,"kind":"organization","name":"Axonics, Inc.","symbol":"AXNX"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-02T21:16:58.000Z","date":"2021-10-22","kind":"grant","acquired":true,"shares":2261,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":14844,"source":{"system":"sec-edgar","filing":"0001562180-21-006778","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1603756/000156218021006778/primarydocument.xml","form_type":"4"}},{"id":2534690,"issuer":{"id":83199,"kind":"organization","name":"Future Health ESG Corp.","symbol":"FHLT"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock, par value $0.0001 per share","published_at":"2021-10-26T16:27:15.000Z","date":"2021-10-24","kind":"disposition_to_issuer","acquired":false,"shares":1689,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the Reporting Person's pecuniary interest in shares forfeited by Future Health ESG Associates 1, LLC to the Issuer on October 24, 2021 for no consideration in connection with the expiration of the underwriters' over-allotment option."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the Reporting Person's pecuniary interest in shares forfeited by Future Health ESG Associates 1, LLC to the Issuer on October 24, 2021 for no consideration in connection with the expiration of the underwriters' over-allotment option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the Reporting Person's pecuniary interest in shares forfeited by Future Health ESG Associates 1, LLC to the Issuer on October 24, 2021 for no consideration in connection with the expiration of the underwriters' over-allotment option."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held directly by Future Health ESG Associates 1, LLC. The Reporting Person disclaims beneficial ownership of the securities held by Future Health ESG Associates 1, LLC except to the extent of her pecuniary interest in the reported securities."}],"balance_after":11262,"source":{"system":"sec-edgar","filing":"0001104659-21-129991","document":"tm2131085-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1851182/000110465921129991/tm2131085-6_4seq1.xml","form_type":"4"}},{"id":2534689,"issuer":{"id":83199,"kind":"organization","name":"Future Health ESG Corp.","symbol":"FHLT"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock, par value $0.0001 per share","published_at":"2021-10-26T16:27:15.000Z","date":"2021-10-24","kind":"disposition_to_issuer","acquired":false,"shares":1688,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 24, 2021, the Report Person forfeited 1,688 shares to the Issuer for no consideration in connection with the expiration of the underwriters' over-allotment option."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 24, 2021, the Report Person forfeited 1,688 shares to the Issuer for no consideration in connection with the expiration of the underwriters' over-allotment option."}],"balance_after":11250,"source":{"system":"sec-edgar","filing":"0001104659-21-129991","document":"tm2131085-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851182/000110465921129991/tm2131085-6_4seq1.xml","form_type":"4"}},{"id":2567960,"issuer":{"id":83199,"kind":"organization","name":"Future Health ESG Corp.","symbol":"FHLT"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant","published_at":"2021-09-16T17:17:27.000Z","date":"2021-09-14","kind":"purchase","acquired":true,"shares":27351,"price":1,"value":27351.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each warrant will become exercisable 30 days after the completion of the Issuer's initial business combination. Each warrant will expire five years after the completion of the Issuer's initial business combination. Each warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustment in the event of certain capital-raising or reorganization transactions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each warrant will become exercisable 30 days after the completion of the Issuer's initial business combination. Each warrant will expire five years after the completion of the Issuer's initial business combination. Each warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustment in the event of certain capital-raising or reorganization transactions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each warrant will become exercisable 30 days after the completion of the Issuer's initial business combination. Each warrant will expire five years after the completion of the Issuer's initial business combination. Each warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustment in the event of certain capital-raising or reorganization transactions."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each warrant will become exercisable 30 days after the completion of the Issuer's initial business combination. Each warrant will expire five years after the completion of the Issuer's initial business combination. Each warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustment in the event of certain capital-raising or reorganization transactions."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each warrant will become exercisable 30 days after the completion of the Issuer's initial business combination. Each warrant will expire five years after the completion of the Issuer's initial business combination. Each warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustment in the event of certain capital-raising or reorganization transactions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held directly by Future Health ESG Associates 1, LLC. The Reporting Person disclaims beneficial ownership of the securities held by Future Health ESG Associates 1, LLC except to the extent of her pecuniary interest in the reported securities."}],"balance_after":27351,"derivative":{"underlying":"See Footnote"},"source":{"system":"sec-edgar","filing":"0001104659-21-116450","document":"tm2127753-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851182/000110465921116450/tm2127753-4_4seq1.xml","form_type":"4"}},{"id":2665695,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Restricted Stock Unit Award","published_at":"2021-06-16T20:28:59.000Z","date":"2021-06-14","kind":"grant","acquired":true,"shares":7585,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares subject to the restricted stock unit award vest in full on 6/14/2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares subject to the restricted stock unit award vest in full on 6/14/2022."}],"balance_after":7585,"derivative":{"exercise_date":"2022-06-14","underlying":"Ordinary Shares","underlying_shares":7585},"source":{"system":"sec-edgar","filing":"0001127602-21-020046","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760221020046/form4.xml","form_type":"4"}},{"id":2665694,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Non Qualified Stock Option (Right to Buy)","published_at":"2021-06-16T20:28:59.000Z","date":"2021-06-14","kind":"grant","acquired":true,"shares":15677,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the stock option award vest and become exercisable in full on 6/14/2022."}],"balance_after":15677,"derivative":{"exercise_price":24.72,"exercise_date":"2022-06-14","expiration_date":"2031-06-14","underlying":"Ordinary Shares","underlying_shares":15677},"source":{"system":"sec-edgar","filing":"0001127602-21-020046","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760221020046/form4.xml","form_type":"4"}},{"id":2690931,"issuer":{"id":46837,"kind":"organization","name":"Lyra Therapeutics, Inc.","symbol":"LYRA"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2021-05-28T22:24:14.000Z","date":"2021-05-26","kind":"grant","acquired":true,"shares":7250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable on the earlier of (i) May 26, 2022 (the one-year anniversary of the date of grant) and (ii) the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date."}],"balance_after":7250,"derivative":{"exercise_price":7.24,"expiration_date":"2031-05-25","underlying":"Common Stock","underlying_shares":7250},"source":{"system":"sec-edgar","filing":"0000899243-21-021187","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1327273/000089924321021187/doc4.xml","form_type":"4"}},{"id":2700394,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Restricted Stock Unit Award","published_at":"2021-05-21T20:38:16.000Z","date":"2021-05-20","kind":"exercise","acquired":false,"shares":6104,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This restricted stock unit award vested in full on 5/20/2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This restricted stock unit award vested in full on 5/20/2021."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Ordinary Shares","underlying_shares":6104},"source":{"system":"sec-edgar","filing":"0001127602-21-017790","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760221017790/form4.xml","form_type":"4"}},{"id":2700393,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2021-05-21T20:38:16.000Z","date":"2021-05-20","kind":"tax_withholding","acquired":false,"shares":1404,"price":21.92,"value":30775.68,"ownership":{"direct":true},"balance_after":4700,"source":{"system":"sec-edgar","filing":"0001127602-21-017790","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760221017790/form4.xml","form_type":"4"}},{"id":2700392,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2021-05-21T20:38:16.000Z","date":"2021-05-20","kind":"exercise","acquired":true,"shares":6104,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6104,"source":{"system":"sec-edgar","filing":"0001127602-21-017790","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760221017790/form4.xml","form_type":"4"}},{"id":2939623,"issuer":{"id":46837,"kind":"organization","name":"Lyra Therapeutics, Inc.","symbol":"LYRA"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-17T21:05:30.000Z","date":"2020-12-16","kind":"purchase","acquired":true,"shares":1025,"price":9.72,"value":9963.0,"ownership":{"direct":true},"balance_after":1025,"source":{"system":"sec-edgar","filing":"0000899243-20-034285","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1327273/000089924320034285/doc4.xml","form_type":"4"}},{"id":2956293,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Restricted Stock Unit Award","published_at":"2020-12-04T21:35:18.000Z","date":"2020-12-02","kind":"grant","acquired":true,"shares":5578,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares subject to the restricted stock unit award vest in full on 12/2/2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares subject to the restricted stock unit award vest in full on 12/2/2021."}],"balance_after":5578,"derivative":{"exercise_price":0,"exercise_date":"2021-12-02","underlying":"Ordinary Shares","underlying_shares":5578},"source":{"system":"sec-edgar","filing":"0001127602-20-030579","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760220030579/form4.xml","form_type":"4"}},{"id":2956292,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Non Qualified Stock Option (Right to Buy)","published_at":"2020-12-04T21:35:18.000Z","date":"2020-12-02","kind":"grant","acquired":true,"shares":11509,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option becomes exercisable in full on 12/2/2021."}],"balance_after":11509,"derivative":{"exercise_price":18.82,"exercise_date":"2021-12-02","expiration_date":"2030-12-02","underlying":"Ordinary Shares","underlying_shares":11509},"source":{"system":"sec-edgar","filing":"0001127602-20-030579","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760220030579/form4.xml","form_type":"4"}},{"id":2997974,"issuer":{"id":46837,"kind":"organization","name":"Lyra Therapeutics, Inc.","symbol":"LYRA"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2020-10-30T00:45:33.000Z","date":"2020-10-27","kind":"grant","acquired":true,"shares":14500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable in 36 monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following October 27, 2020."}],"balance_after":14500,"derivative":{"exercise_price":11.76,"expiration_date":"2030-10-26","underlying":"Common Stock","underlying_shares":14500},"source":{"system":"sec-edgar","filing":"0000899243-20-029782","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1327273/000089924320029782/doc4.xml","form_type":"4"}},{"id":3046054,"issuer":{"id":86004,"kind":"organization","name":"Axonics, Inc.","symbol":"AXNX"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-08-26T20:18:17.000Z","date":"2020-08-24","kind":"grant","acquired":true,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":12583,"source":{"system":"sec-edgar","filing":"0001562180-20-005682","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1603756/000156218020005682/primarydocument.xml","form_type":"4"}},{"id":3136629,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Restricted Stock Unit Award","published_at":"2020-05-22T20:24:34.000Z","date":"2020-05-20","kind":"grant","acquired":true,"shares":6104,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This option and restricted stock unit award together represent 50% of the approved value of the non-employee director annual equity grant. The remaining portion of such grant has been delayed, and is subject to downward adjustment, due to the uncertainty posed by the COVID-19 pandemic."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares subject to the restricted stock unit award vest in full on 5/20/2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares subject to the restricted stock unit award vest in full on 5/20/2021."}],"balance_after":6104,"derivative":{"exercise_price":0,"exercise_date":"2021-05-20","underlying":"Ordinary Shares","underlying_shares":6104},"source":{"system":"sec-edgar","filing":"0001127602-20-017776","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760220017776/form4.xml","form_type":"4"}},{"id":3136628,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Non Qualified Stock Option (Right to Buy)","published_at":"2020-05-22T20:24:34.000Z","date":"2020-05-20","kind":"grant","acquired":true,"shares":12823,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This option and restricted stock unit award together represent 50% of the approved value of the non-employee director annual equity grant. The remaining portion of such grant has been delayed, and is subject to downward adjustment, due to the uncertainty posed by the COVID-19 pandemic."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option becomes exercisable in full on 5/20/2021."}],"balance_after":12823,"derivative":{"exercise_price":16.85,"exercise_date":"2021-05-20","expiration_date":"2030-05-20","underlying":"Ordinary Shares","underlying_shares":12823},"source":{"system":"sec-edgar","filing":"0001127602-20-017776","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760220017776/form4.xml","form_type":"4"}},{"id":3429014,"issuer":{"id":86004,"kind":"organization","name":"Axonics, Inc.","symbol":"AXNX"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-08-26T18:59:08.000Z","date":"2019-08-22","kind":"grant","acquired":true,"shares":4167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on August 18, 2020."}],"balance_after":4167,"derivative":{"exercise_price":34.1,"expiration_date":"2029-08-22","underlying":"Common Stock","underlying_shares":4167},"source":{"system":"sec-edgar","filing":"0001562180-19-004492","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1603756/000156218019004492/primarydocument.xml","form_type":"4"}},{"id":3429013,"issuer":{"id":86004,"kind":"organization","name":"Axonics, Inc.","symbol":"AXNX"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-26T18:59:08.000Z","date":"2019-08-22","kind":"grant","acquired":true,"shares":2083,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":9083,"source":{"system":"sec-edgar","filing":"0001562180-19-004492","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1603756/000156218019004492/primarydocument.xml","form_type":"4"}},{"id":3474305,"issuer":{"id":86004,"kind":"organization","name":"Axonics, Inc.","symbol":"AXNX"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-01T18:51:40.000Z","date":"2019-06-27","kind":"purchase","acquired":true,"shares":2000,"price":37.12,"value":74240.0,"ownership":{"direct":true},"balance_after":7000,"source":{"system":"sec-edgar","filing":"0001562180-19-003721","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1603756/000156218019003721/primarydocument.xml","form_type":"4"}},{"id":3513041,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Non Qualified Stock Option (Right to Buy)","published_at":"2019-05-23T22:38:06.000Z","date":"2019-05-22","kind":"grant","acquired":true,"shares":22400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option becomes exercisable in full on 5/22/2020."}],"balance_after":22400,"derivative":{"exercise_price":25.04,"exercise_date":"2020-05-22","expiration_date":"2029-05-22","underlying":"Ordinary Shares","underlying_shares":22400},"source":{"system":"sec-edgar","filing":"0001127602-19-019717","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760219019717/form4.xml","form_type":"4"}},{"id":3559076,"issuer":{"id":86004,"kind":"organization","name":"Axonics, Inc.","symbol":"AXNX"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-04-09T21:20:48.000Z","date":"2019-04-08","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable in full on April 8, 2020, provided the reporting person remains in continuous service through such date."}],"balance_after":10000,"derivative":{"exercise_price":21.04,"expiration_date":"2029-04-08","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-19-010424","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1603756/000089924319010424/doc4.xml","form_type":"4"}},{"id":3559075,"issuer":{"id":86004,"kind":"organization","name":"Axonics, Inc.","symbol":"AXNX"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-09T21:20:48.000Z","date":"2019-04-08","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0000899243-19-010424","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1603756/000089924319010424/doc4.xml","form_type":"4"}},{"id":3918232,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Non Qualified Stock Option (Right to Buy)","published_at":"2018-05-24T22:27:27.000Z","date":"2018-05-23","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option becomes exercisable in full on 5/23/19."}],"balance_after":17500,"derivative":{"exercise_price":45.64,"exercise_date":"2019-05-23","expiration_date":"2028-05-23","underlying":"Ordinary Shares","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001127602-18-018855","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760218018855/form4.xml","form_type":"4"}},{"id":4304322,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Non Qualified Stock Option (Right to Buy)","published_at":"2017-05-25T22:05:33.000Z","date":"2017-05-24","kind":"grant","acquired":true,"shares":14200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option becomes exercisable in full on 5/24/18."}],"balance_after":14200,"derivative":{"exercise_price":58.25,"exercise_date":"2018-05-24","expiration_date":"2027-05-24","underlying":"Ordinary Shares","underlying_shares":14200},"source":{"system":"sec-edgar","filing":"0001127602-17-019450","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760217019450/form4.xml","form_type":"4"}},{"id":4602573,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Non Qualified Stock Option (Right to Buy)","published_at":"2016-09-15T21:03:50.000Z","date":"2016-09-14","kind":"grant","acquired":true,"shares":16200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option becomes exercisable in full on 9/14/17."}],"balance_after":16200,"derivative":{"exercise_price":47.65,"exercise_date":"2017-09-14","expiration_date":"2026-09-14","underlying":"Ordinary Shares","underlying_shares":16200},"source":{"system":"sec-edgar","filing":"0001127602-16-062563","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760216062563/form4.xml","form_type":"4"}},{"id":4602572,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":27121,"kind":"person","name":"snyderman nancy lynn MD","position":1,"cik":"0001675198","reported_name":"snyderman nancy lynn MD","relationship":{"director":true}}],"security":"Non Qualified Stock Option (Right to Buy)","published_at":"2016-09-15T21:03:50.000Z","date":"2016-09-14","kind":"grant","acquired":true,"shares":27400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in 3 equal annual installments commencing on 9/14/17."}],"balance_after":27400,"derivative":{"exercise_price":47.65,"exercise_date":"2017-09-14","expiration_date":"2026-09-14","underlying":"Ordinary Shares","underlying_shares":27400},"source":{"system":"sec-edgar","filing":"0001127602-16-062563","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1520262/000112760216062563/form4.xml","form_type":"4"}}]}